<DOC>
	<DOCNO>NCT00552500</DOCNO>
	<brief_summary>This project aim ) evaluate effect haloperidol , olanzapine , risperidone combination valproate insulin secretion insulin action , b ) evaluate medication effect abdominal fat , total body fat total fat-free mass , c ) evaluate treatment effect glucose tolerance , lipid profile , plasma level leptin , adiponectin , ghrelin C-reactive protein . Hypotheses evaluate measure 1 ) insulin action secretion use frequently sample intravenous glucose tolerance test , 2 ) body composition use dual energy x-ray absorptiometry , magnetic resonance scan , anthropomorphic measurement , 3 ) change hormone level lipid profile . The aim address non-diabetic schizophrenia patient chronically treat haloperidol , olanzapine risperidone valproate add treatment . Relevant data critically need target basic research , identify long-term cardiovascular risk , plan therapeutic intervention .</brief_summary>
	<brief_title>Effects Atypical Antipsychotic Valproate Combination Therapy Glucose Lipid Metabolism Schizophrenia</brief_title>
	<detailed_description>Schizophrenia associate increase rate obesity , hyperglycemia , dyslipidemia type 2 diabetes mellitus , cause increase morbidity mortality due acute ( e.g. , diabetic ketoacidosis ) long-term ( e.g. , vascular disease ) complication . The association type 2 diabetes hyperglycemia schizophrenia first note prior introduction antipsychotic medication . However , additional glucoregulatory abnormality , dyslipidemia , increase adiposity associate antipsychotic . Risperidone olanzapine prescribe antipsychotic schizophrenia U.S . In addition , schizophrenia patient clinical practice commonly treat multi-class polypharmacy , 35 % atypical antipsychotic prescription accompany co-prescription valproate . This combination continue increase popularity , despite report addition valproate may disturb glucose lipid metabolism weight regulation . While sensitive validated measure glucose lipid metabolism weight regulation available , study address metabolic consequence common type polypharmacy . This project aim ) evaluate effect haloperidol , olanzapine , risperidone combination valproate insulin secretion insulin action , b ) evaluate medication effect abdominal fat , total body fat total fat-free mass , c ) evaluate treatment effect glucose tolerance , lipid profile , plasma level leptin , adiponectin , ghrelin C-reactive protein . Hypotheses evaluate measure 1 ) insulin action secretion use frequently sample intravenous glucose tolerance test , 2 ) body composition use dual energy x-ray absorptiometry , magnetic resonance scan , anthropomorphic measurement , 3 ) change hormone level lipid profile . The aim address non-diabetic schizophrenia patient chronically treat haloperidol , olanzapine risperidone valproate add treatment . Relevant data critically need target basic research , identify long-term cardiovascular risk , plan therapeutic intervention .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<criteria>Meets DSMIV criterion schizophrenia , type , treat atypical high potency typical neuroleptic least 3 month Aged 18 60 year Able give inform consent No antipsychotic medication change 3 month , medication change 2 week prior Baseline Evaluations . Meets DSMIV criterion diagnose substance abuse dependence within past 6 month Involuntary legal status ( per Missouri law ) The presence serious medical disorder may ( confirm peerreviewed literature ) confound assessment symptom , relevant biologic measure diagnosis . The following condition currently identify : Type 1 diabetes mellitus symptomatic type 2 diabetes mellitus Any intraabdominal intrathoracic surgery limb amputation within prior 6 month Any diagnosed cardiac condition cause document hemodynamic compromise Any diagnose respiratory condition cause document clinically recognize hypoxia Pregnancy high dose estrogen , fever , narcotic therapy , acute sedative hypnotic withdrawal , corticosteroid spironolactone therapy , dehydration , epilepsy , endocrine disease , highdose benzodiazepine therapy ( &gt; 25 mg/day diazepam ) , medical condition know interfere glucose utilization Meets DSMIV criterion Mental Retardation ( mild worse ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2010</verification_date>
</DOC>